Breast Cancer Clinical Trial
Official title:
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
This is an open-label study of INCB047986 given to two distinct groups of patients (Group 1
and Group 2) with advanced malignancies. The purpose of the study is to evaluate the safety,
tolerability and pharmacokinetics of INCB047986 and to determine the maximum tolerated dose
of INCB047986 in combination with gemcitabine and nab paclitaxel in a select group of
patients with solid tumors. Each patient group will participate in a phase of the study which
is divided into two parts. The patient groups will be enrolled in a sequential manner
starting with Patient Group 1.
Patient Group 1
Group 1 will be comprised of patients with advanced malignancies who will receive INCB047986
as monotherapy.
Part 1: Dose Escalation Phase - This phase will evaluate the safety, tolerability and
pharmacokinetics (PK) of INCB047986 when given as described to patients with advanced
malignancies. A goal of Part 1 will be to identify the maximally tolerated dose (MTD) of
INCB047986 and/or other dose(s) that are tolerated doses and produce a substantial
pharmacologic effect. These doses will be used in Part 2 of the study.
Part 2: Expansion Phase - This phase will further explore the safety, tolerability, PK, and
preliminary clinical activity of INCB047986 using the doses identified in Part 1.
Group 2
Group 2 will be in subjects with advanced or metastatic pancreatic cancer, breast cancer or
urothelial cancer.
Part 1: Dose Optimization Phase - This phase will identify the MTD of INCB047986 in
combination with gemcitabine and nab-paclitaxel in patients with advanced or metastatic solid
tumors. Specifically, these will be patients with pancreatic adenocarcinoma (first or second
line), triple-negative breast cancer (second line) or urothelial cancer (second line).
Part 2: Expansion Phase - This phase will explore the safety, tolerability, PK, biomarkers,
and preliminary clinical activity of the dose regimen(s) identified in Part 1. Patients
enrolled in this phase will be limited to those with advanced or metastatic pancreatic
cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |